Mario M. Leitao, Jr, MD, FACOG, FACS, program director of Gynecologic Oncology at Memorial Sloan Kettering Cancer Center, discusses what is currently being investigated in the treatment landscape of ovarian cancers.
Mario M. Leitao, Jr, MD, FACOG, FACS, program director of Gynecologic Oncology at Memorial Sloan Kettering Cancer Center, discusses what is currently being investigated in the treatment landscape of ovarian cancers.
There is a lot of discussion on hypothermic intraperitoneal chemotherapy (HIPEC), which is currently only available to patients on a clinical trial, Leitao says. HIPEC is currently being tested in a phase II trial at Memorial Sloan Kettering. Leitao says he hopes this can add value to patients as a treatment, but it does require more time.
Leitao expects PARP inhibitors will head to the frontline setting for treatment of patients with ovarian cancer, though it is not there yet. His lab is currently running clinical trials on immunotherapies as a treatment in the neoadjuvant setting. He hopes to see if there is an improvement in survival or progression after adding immunotherapy drugs to platinum-paclitaxel based treatments.
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More